Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: hepatitis A vaccine Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Persistent Innate Immune Activation on Vaccine Efficacy

NCT02429583
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Recombivax
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 62 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 3, 2026, 10:55 AM EDT
Completed No phase listed Observational

Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant

NCT03511794
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

HerpeVac Trial for Young Women

NCT00057330
View directory record Official record
Conditions
Herpes Simplex Infection
Interventions
HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 30 Years · Female only
Enrollment
8,323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 3, 2026, 10:55 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose

NCT06855836
View directory record Official record
Conditions
Overdose
Interventions
MI-CHANCE (TS + FTIR + MI), TS + FTIR + Flu and Hepatitis A Education
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Recruiting Phase 4 Interventional

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

NCT04588077
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Interventions
Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
Biological
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

NCT03530124
View directory record Official record
Conditions
Apnea, Apnea Neonatal, Prematurity
Interventions
PCV13, DTaP, HBV, IPV, Hib
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Weeks and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 3, 2026, 10:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

NCT00142740
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 25 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
4
States / cities
Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

NCT00197236
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix™, Infanrix™, ActHIB™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 3, 2026, 10:55 AM EDT
Completed No phase listed Observational

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

NCT01282762
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

NCT00926146
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions
NCMIT, SCMIT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
451 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Not applicable Interventional

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

NCT00000896
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
San Diego, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)

NCT00958763
View directory record Official record
Conditions
Hepatitis C
Interventions
Motivational Interviewing, Single - MIS, Motivational Interviewing Group, Usual Care Group - UCG
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Chiron Corp HCV E1/E2 Vaccine

NCT00500747
View directory record Official record
Conditions
Hepatitis C
Interventions
HCV E1E2/MF59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03691610
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 19 Months
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 3, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

NCT01311674
View directory record Official record
Conditions
Healthy Volunteers
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
20 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Altamonte Springs, Florida • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 3, 2026, 10:55 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT06740630
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

NCT03207750
View directory record Official record
Conditions
Rotavirus Infection, Rotavirus Vaccines
Interventions
Rotarix, Pediarix, Hiberix, Prevenar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

NCT01830855
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
rLP2086, Havrix (HAV), Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
3,596 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 3, 2026, 10:55 AM EDT
Completed No phase listed Observational

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

NCT02747407
View directory record Official record
Conditions
Astrocytoma, Glioma, Oligodendroglioma
Interventions
Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 3, 2026, 10:55 AM EDT
Recruiting Phase 4 Interventional

Vaccine Responses in Patients With B Cell Malignancies

NCT05170399
View directory record Official record
Conditions
Lymphoma
Interventions
AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23, Heplisav -B, PREVNAR 13, Shingrix
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 3, 2026, 10:55 AM EDT